期刊名称：JOURNAL OF DRUG ISSUES
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
The Journal of Drug Issues (JDI) was incorporated as a nonprofit entity in the State of Florida in 1971. In 1996, JDI was transferred to the Florida State University School of Criminology and Criminal Justice, and the Richard L. Rachin Endowment was established to support its continued publication. Since its inception, JDI has been dedicated to providing a professional and scholarly forum centered on the national and international problems associated with drugs, especially illicit drugs. It is a refereed publication with international contributors and subscribers. As a leader in its field, JDI is an instrument widely used by research scholars, public policy analysts, and those involved in the day-to-day struggle against the problem of drug abuse.
Instructions to Authors
MANUSCRIPT
Submit four hard copies along with the electronic file (CD or floppy disk) of your article. Manuscripts should be double-spaced, including references. Send manuscripts to Bruce Bullington, Editor, Journal of Drug Issues, Florida State University, 634 West Call Street, Tallahassee, FL 32306-1127. Only previously unpublished manuscripts are accepted for exclusive review. Manuscripts should not be submitted to JDI if they are under consideration by other journals. Upon acceptance, articles become the exclusive property of the Journal. Authors are responsible for obtaining the Journal's permission to use and reprint copyrighted materials. After acceptance submit article via electronic mail or on one 3-1/2 inch DOS formatted floppy disk.
PREPARATION
Manuscripts should not exceed 20 pages of text. Prepare text in Times New Roman 11 point type. Do not use automatic endnote function in your word processing program. Endnote marks in the text should simply be superscripted numbers, and notes should be typed separately at the end of the text. For reference on style, see the Publication Manual of the American Psychological Association, 5th ed.
REVIEW
To facilitate anonymous review, only the title of the article should appear on the front page. Names, affiliations, complete mailing addresses, e-mail addresses, phone numbers, and fax numbers of all authors should be included on a separate cover page. Authors should keep a copy of their manuscripts.
ABSTRACT AND BIOGRAPHICAL SKETCHES
An abstract not to exceed 150 words and biographical sketches not to exceed 50 words for each author should be provided.
RUNNING HEAD
Submit a short running title of no more than 55 characters, including spaces.
HEADINGS
First level headings should be bold and aligned left. Second-level headings should be italicized and aligned left. Third-level headings should be italicized and indented:
First-Level Heading
Second-Level Heading
Third-Level Heading
TABLES AND FIGURES
Tables should be prepared in Times New Roman 10 point type. Table notes should be prepared in Times New Roman 9 point type. A location in the text for each table and figure should be indicated, e.g., Table 1 about here, and tables should appear after the reference list.
JDI possesses the exclusive right of original publication. While authors are permitted unlimited use of their articles, copyright of the collected work is held by the Journal of Drug Issues. Requests for permission to reprint an article should be submitted to the Journal of Drug Issues. Statements and opinions expressed in the articles herein are those of the author(s) and do not necessarily express those of the publisher or editors or the Journal of Drug Issues.
Editorial Board
|
Editorial Board
FOUNDER: Richard L. Rachin (1931-1995), Editor, 1970-1995
EDITOR: Bruce Bullington, Florida State University
ASSOCIATE EDITORS
- Ron Akers, University of Florida
- Laura Bedard, Florida Department of Corrections
- Pavel Bem, The National Drug Commission of the Czech Republic
- Bruce Benson, Florida State University
- William R. Blount, University of South Florida
- Lorenz Boellinger, Bremen University (Germany)
- Robert Booth, University of Colorado
- Robert S. Broadhead, University of Connecticut
- Barry S. Brown, University of North Carolina
- Khanh Bui, Pepperdine University
- William M. Burdon, UCLA Integrated Substance Abuse Programs
- Shane Butler, Trinity College, Dublin
- Jonathan P. Caulkins, Carnegie Mellon University
- Ted Chiricos, Florida State University
- John K. Cochran, University of South Florida
- Ross Coomber, University of Plymouth (England)
- C. Elaine Cummins, University of Michigan
- Geoffrey M. Curran, University of Arkansas for Medical Sciences
- Dean Dabney, Georgia State University
- Shane Darke, University of New South Wales (Australia)
- Tom Decorte, Ghent University (Belgium)
- Richard Dembo, University of South Florida
- Sergiy Dvoryak, Ukrainian Institute on Public Health Policy
- Patricia Erickson, Centre for Addiction & Mental Health, Toronto
- Michael Fendrich, University of Wisconsin, Milwaukee
- Stefano Ferracuti, University of Rome (Italy)
- Robert Fiorentine, UCLA Drug Abuse Research Center
- Juan Gamella, Universidad de Granada (Spain)
- Andrew Golub, National Development and Research Institutes, Inc.
- Christine E. Grella, UCLA Drug Abuse Research Center
- Joseph R. Guydish, University of California, San Francisco
- Elizabeth A. Hall, University of California, Los Angeles
- Geoffrey P. Hunt, Institute for Scientific Analysis
- Martin Iguchi, RAND
- James Inciardi, University of Delaware
- Dirk J. Korf, University of Amsterdam (The Netherlands)
- Ludwig Kraus, IFT Institut fur Therapieforschung (Germany)
- Christopher P. Krebs, Research Triangle Institute
- Spencer Li, Westat
| |
|
